Cell Therapeutics, Inc. and US Oncology, Inc. Join Forces to Advance PG-TXL(TM) Phase II Development

Up to Five Clinical Trials Planned in Colorectal and Lung Cancer



Apr 25, 2001, 01:00 ET from Cell Therapeutics, Inc.

    SEATTLE, April 25 /PRNewswire/ -- Cell Therapeutics, Inc. (cti)
 (Nasdaq:   CTIC) and US Oncology, Inc. (Nasdaq:   USON) have entered into a
 research services agreement under which US Oncology will conduct up to five
 clinical studies in colorectal and lung cancers with cti's PG-TXL.
     "We are excited to be working with Cell Therapeutics on this novel drug
 candidate," noted Alan Keller, M.D., co-Medical Director of Clinical Research
 at US Oncology.  "We are enthusiastic about playing a significant role in the
 clinical development of this drug because of the ease of administration, as
 well as the potential for reduction in neurologic toxicity and improved
 anti-tumor activity."
     PG-TXL links paclitaxel, the active ingredient in the world's best selling
 cancer drug Taxol(R), to a biodegradable polyglutamate polymer.  PG-TXL is
 currently in a single-agent Phase I clinical trial in the United Kingdom and
 in Phase I/II trials as single-agent therapy and in combination with other
 drugs in the United States.
     "We believe working with a premier organization like US Oncology will
 assist us in accelerating patient enrollment for these indications," said
 James A. Bianco, M.D. President and CEO of cti.  "We could begin to see some
 preliminary data from these clinical trials later this year at the major
 cancer meetings."
 
     About Colorectal Cancer
     Excluding skin cancers, colorectal cancer is the third most common cancer
 diagnosed in men and women in the United States.  The American Cancer Society
 estimates that about 98,200 new cases of colon cancer (46,200 men and
 52,000 women) and 37,200 new cases of rectal cancer (21,100 men and
 16,100 women) will be diagnosed in 2001.
     Colon cancer is expected to be responsible for about 48,100 deaths
 (23,000 men and 25,100 women) during 2001.  About 8,600 people (4,700 men and
 3,900 women) will die from rectal cancer during 2001.
 
     About Lung Cancer
     According to the American Cancer Society, during 2001, there will be about
 169,500 new cases of lung cancer (90,700 among men and 78,800 among women).
 Lung cancer will account for about 13.4% of all new cancers.  The average age
 of people diagnosed with lung cancer is 60; it is unusual under the age of
 40.
     Lung cancer is the leading cause of cancer death among both men and women.
 There will be an estimated 157,400 deaths from lung cancer (90,100 among men
 and 67,300 among women) in 2001, accounting for 28% of all cancer deaths.
 More people die of lung cancer than of colon, breast, and prostate cancers
 combined.
 
     About US Oncology, Inc.
     US Oncology, Inc. (www.usoncology.com) represents the nation's most
 extensive oncology network, including cancer research, diagnostic and
 radiation centers, outpatient blood and marrow stem cell transplant, and
 pharmaceutical management services.  The research group, within US Oncology,
 offers an integrated platform for conducting Phase I through Phase IV clinical
 trials for new and approved cancer therapies through US Oncology's
 community-based physician practices and cancer centers.  The US Oncology
 network operates in 27 states with over 865 affiliated physicians in
 492 locations, including 72 integrated cancer centers.
 
     About Cell Therapeutics, Inc.
     cti (www.cticseattle.com) is committed to developing an integrated
 portfolio of oncology products aimed at making cancer more treatable.  In
 addition to PG-TXL, TRISENOX(TM) (arsenic trioxide) injection was approved by
 the Food and Drug Administration to treat patients with relapsed or refractory
 acute promyelocytic leukemia.  The Company is also developing two other drug
 candidates:  CT-2584, a novel anti-cancer drug candidate in Phase II clinical
 trials for patients with cancers that have become resistant to conventional
 chemotherapy, such as soft tissue sarcoma and prostate cancer and PG-CPT,
 which links a camptothecin to the polyglutamate backbone.
     This announcement includes forward-looking statements that involve a
 number of risks and uncertainties, the outcome of which could materially
 and/or adversely affect actual future results.  Specifically, the risks and
 uncertainties that could affect the development of cti's products under
 development include risks associated with preclinical and clinical
 developments in the biopharmaceutical industry in general and of cti's
 products under development in particular including, without limitation, the
 potential failure of all compounds to prove safe and effective for treatment
 of disease, determinations by regulatory, patent and administrative
 governmental authorities, competitive factors, technological developments,
 costs of developing, producing and selling cti's products under development,
 and the risk factors listed or described from time to time in the Company's
 filings with the Securities and Exchange Commission including, without
 limitation, the Company's most recent registrations on Forms 10-K, 8-K, S-3
 and 10-Q.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X63241514
 
 

SOURCE Cell Therapeutics, Inc.
    SEATTLE, April 25 /PRNewswire/ -- Cell Therapeutics, Inc. (cti)
 (Nasdaq:   CTIC) and US Oncology, Inc. (Nasdaq:   USON) have entered into a
 research services agreement under which US Oncology will conduct up to five
 clinical studies in colorectal and lung cancers with cti's PG-TXL.
     "We are excited to be working with Cell Therapeutics on this novel drug
 candidate," noted Alan Keller, M.D., co-Medical Director of Clinical Research
 at US Oncology.  "We are enthusiastic about playing a significant role in the
 clinical development of this drug because of the ease of administration, as
 well as the potential for reduction in neurologic toxicity and improved
 anti-tumor activity."
     PG-TXL links paclitaxel, the active ingredient in the world's best selling
 cancer drug Taxol(R), to a biodegradable polyglutamate polymer.  PG-TXL is
 currently in a single-agent Phase I clinical trial in the United Kingdom and
 in Phase I/II trials as single-agent therapy and in combination with other
 drugs in the United States.
     "We believe working with a premier organization like US Oncology will
 assist us in accelerating patient enrollment for these indications," said
 James A. Bianco, M.D. President and CEO of cti.  "We could begin to see some
 preliminary data from these clinical trials later this year at the major
 cancer meetings."
 
     About Colorectal Cancer
     Excluding skin cancers, colorectal cancer is the third most common cancer
 diagnosed in men and women in the United States.  The American Cancer Society
 estimates that about 98,200 new cases of colon cancer (46,200 men and
 52,000 women) and 37,200 new cases of rectal cancer (21,100 men and
 16,100 women) will be diagnosed in 2001.
     Colon cancer is expected to be responsible for about 48,100 deaths
 (23,000 men and 25,100 women) during 2001.  About 8,600 people (4,700 men and
 3,900 women) will die from rectal cancer during 2001.
 
     About Lung Cancer
     According to the American Cancer Society, during 2001, there will be about
 169,500 new cases of lung cancer (90,700 among men and 78,800 among women).
 Lung cancer will account for about 13.4% of all new cancers.  The average age
 of people diagnosed with lung cancer is 60; it is unusual under the age of
 40.
     Lung cancer is the leading cause of cancer death among both men and women.
 There will be an estimated 157,400 deaths from lung cancer (90,100 among men
 and 67,300 among women) in 2001, accounting for 28% of all cancer deaths.
 More people die of lung cancer than of colon, breast, and prostate cancers
 combined.
 
     About US Oncology, Inc.
     US Oncology, Inc. (www.usoncology.com) represents the nation's most
 extensive oncology network, including cancer research, diagnostic and
 radiation centers, outpatient blood and marrow stem cell transplant, and
 pharmaceutical management services.  The research group, within US Oncology,
 offers an integrated platform for conducting Phase I through Phase IV clinical
 trials for new and approved cancer therapies through US Oncology's
 community-based physician practices and cancer centers.  The US Oncology
 network operates in 27 states with over 865 affiliated physicians in
 492 locations, including 72 integrated cancer centers.
 
     About Cell Therapeutics, Inc.
     cti (www.cticseattle.com) is committed to developing an integrated
 portfolio of oncology products aimed at making cancer more treatable.  In
 addition to PG-TXL, TRISENOX(TM) (arsenic trioxide) injection was approved by
 the Food and Drug Administration to treat patients with relapsed or refractory
 acute promyelocytic leukemia.  The Company is also developing two other drug
 candidates:  CT-2584, a novel anti-cancer drug candidate in Phase II clinical
 trials for patients with cancers that have become resistant to conventional
 chemotherapy, such as soft tissue sarcoma and prostate cancer and PG-CPT,
 which links a camptothecin to the polyglutamate backbone.
     This announcement includes forward-looking statements that involve a
 number of risks and uncertainties, the outcome of which could materially
 and/or adversely affect actual future results.  Specifically, the risks and
 uncertainties that could affect the development of cti's products under
 development include risks associated with preclinical and clinical
 developments in the biopharmaceutical industry in general and of cti's
 products under development in particular including, without limitation, the
 potential failure of all compounds to prove safe and effective for treatment
 of disease, determinations by regulatory, patent and administrative
 governmental authorities, competitive factors, technological developments,
 costs of developing, producing and selling cti's products under development,
 and the risk factors listed or described from time to time in the Company's
 filings with the Securities and Exchange Commission including, without
 limitation, the Company's most recent registrations on Forms 10-K, 8-K, S-3
 and 10-Q.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X63241514
 
 SOURCE  Cell Therapeutics, Inc.